Quantx Biosciences closed an $85 million Series B to advance two oral immunology candidates: a STAT6 small‑molecule inhibitor and an IL‑17 oral inhibitor. The oversubscribed financing funds IND‑enabling activities and early clinical testing, the company said. Quantx is positioning its computationally driven discovery platform as the engine behind its lead candidates; investors bet the cash will speed the transition to human studies. The raise underscores continued VC appetite for oral immunology programs that could compete with injectable biologics across allergic and inflammatory indications.